



Marinus Pharmaceuticals  
Investor Relations Department  
170 N. Radnor Chester Road,  
Suite 250  
Radnor, PA 19087-5279  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: MRNS

Last Trade:	1.71
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	0.03 <span style="color: green;">▲</span> (+1.786%)
Day Range	1.64 - 1.73
52-Week Range	0.82 - 2.73
Volume	272,544


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 29, 2017*

[FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder](#)

*Jun 27, 2017*

[Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression](#)

*May 1, 2017*

[Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results](#)

*Apr 18, 2017*

[Marinus to present Ganaxolone DATA at American academy of neurology annual meeting](#)

*Apr 11, 2017*

[Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer](#)

## Upcoming Events [\[ View all \]](#)

*Sep 6, 2017*

[International Epilepsy Congress](#)

## Financials & Filings [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 13, 2017*

[Annual Report \(10-K\)](#)

*Mar 16, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 1, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 9, 2016*

[Quarterly Report \(10-Q\)](#)